个人信息 |
姓名: 李永奎 部门: 病原微生物研究院 直属机构: 病原微生物研究院 性别: 男 职务: 教师 职称: 副教授 学位: 博士 毕业院校: 武汉大学 联系电话: 020-85220627 电子邮箱: lyk070@jnu.edu.cn 办公地址: 暨南大学成教楼712 通讯地址: 广州市黄埔大道西601号 邮编: 510632 传真: 荣誉奖励: |
联系方式 |
|
个人简介发表SCI学术论文15篇,其中第一作者论文8篇,包括在Cancer Research,Protein Cell,Journal of Biological Chemistry, Oncoimmunology等权威SCI杂志各一篇。论文累计被他人引用总次数>560次,H指数为11,其中第一作者论文(Protein Cell)单篇被他人引用>100次。获授权的国家发明专利2项。主持人承担科研项目6项,包含1项国家自然科学基金,1项广东省自然科学基金, 参与科研项目5项。 首次发现并报道了直接调控III型干扰素的小分子RNA,阐明了其通过作用于III型干扰素调节细胞在病毒感染中的天然免疫机制。作为第一完成人的论文(Protein Cell. 2013; 4 (2): 130-41)发表后受到病毒学和免疫学领域同行的广泛关注,被所在杂志社Protein Cell评为高水平论文,并收到杂志主编饶子和院士的感谢信。2013年开始与密歇根大学著名免疫学家邹伟平教授(Weiping Zou,PD-1配体的发现者,肿瘤免疫抑制理论和PD-1免疫治疗的奠基人)深入合作,研究白细胞介素33 在结直肠癌发生发展过程的作用,发现白细胞介素33促进结直肠癌干细胞活性并阐明其机制,成果以共同第一作者在肿瘤学权威杂志Cancer Research发表论文,是肿瘤免疫领域属标志性成果,因此作为该杂志当期封面论文发表(Cancer Research. 2017;77(10):2735-2745.)。2014-2016年在武汉协和医院与王琳教授团队合作研发的“新型丝胶生物材料”在肿瘤治疗、组织创伤修复和抑制炎症反应中效果显著,具有很高的临床应用价值,该研究成果被中央电视台《新闻联播》和《走进科学》栏目先后进行报道。本人作为共同发明人获得国家专利授权,并作为完成人之一,荣获2017年湖北省科技进步一等奖。 学习经历2007/9 - 2012/12,武汉大学,生命科学学院,病毒学国家重点实验室,博士(硕博连读); 2003/9 - 2007/7,武汉大学,生命科学学院,生命科学与技术基地班,本科 工作经历2019/01 - 至今,暨南大学,病原微生物研究院,副教授; 2013/01 – 2018/12,华中科技大学,同济医学院附属协和医院,助理研究员 研究方向病毒感染、肿瘤等疾病过程中的炎症与免疫反应;活性生物材料的研究与应用。 主要论文[1] Xiuli Ding#, Chen Peng#, Yongkui Li#, Jia Liu, Yu Song, Bo Cai, Mengxi Xiang, Jian Zhang, Zheng Wang*, Lin Wang* Targeting inhibition of Foxp3 by MMP2/9 sensitive short peptide linked P60 fusion protein 6(P60- MMPs) to enhance anti-tumor immunity. Macromolecular Bioscience. 2020 May 25:e2000098. (共同一作, IF = 2.895,中科院分区2区) [2]Qi Shanshan#, Li Yongkui#, Dai Zhen, Xiang Mengxi, Wang Guobin, Wang Lin, Wang Zheng. Uhrf1-Mediated Tnf-α Gene Methylation Controls Proinflammatory Macrophages in Experimental Colitis Resembling Inflammatory Bowel Disease. J Immunol. 2019 Oct 14.(共同一作,IF = 4.718,中科院分区2区) [3] Yongli Fan#, Yongkui Li#, Jian Zhang, Xiuli Ding, Jinyuan Cui, Guobin Wang*, Zheng Wang*, Lin Wang*. Alginate Enhances Memory Properties of Antitumor CD8+ T Cells by Promoting Cellular Antioxidation.ACS Biomaterials Science & Engineering (July 24, 2019)https://doi.org/10.1021/acsbiomaterials.9b00373 (共同一作,IF = 4.432, 中科院分区2区) [4]Yongkui Li#, Jie Shi#, Shanshan Qi, Jian Zhang, Dong Peng, Zhenzhen Chen, Guobin Wang*, Zheng Wang*, and Lin Wang*. IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2.Journal of Experimental & Clinical Cancer Research (2018) 37:196. (IF = 6.217, 中科院分区2区) [5] Min Fang#,Yongkui Li#, Kai Huang#, Shanshan Qi, Jian Zhang,Witold Zgodzinski, Marek Majewski, Grzegorz Wallner, Stanislaw Gozdz, Pawel Macek, Artur Kowalik, Marcin Pasiarski, Ewelina Grywalska, Linda Vatan, Nisha Nagarsheth,Wei Li, Lili Zhao, Ilona Kryczek, Guobin Wang, Zheng Wang,Weiping Zou, and Lin Wang. IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. Cancer Research. 2017 May 15;77(10):2735-2745. (共同一作,IF = 9.13,中科院分区1区) [6] Yongkui Li#, Min Fang#, Jian Zhang, Jian Wang, Yu Song, Jie Shi, Wei Li, Gang Wu, Jinghua Ren, Zheng Wang, Weiping Zou, and Lin Wang. Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology.2015 Aug 12;5(2):e1074374. (IF = 7.719,中科院分区1区) [7] Yongkui Li#, Jiajia Xie#, Xiupeng Xu, Li Liu, Yushun Wan, Yingle Liu, Zhu Ying*. Inducible IL-32 exerts extensive antiviral function via selective stimulation of IFN-lambda1.Journal of Biological Chemistry. 2013; 288(29):20927–41. (IF = 4.600, 中科院分区2区) [8] Yongkui Li, Jiajia Xie, Xiupeng Xu, Jun Wang, Fang Ao, Yushun Wan, Ying Zhu*. MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-lambda1. Protein Cell. 2013; 4 (2): 130-41. (IF = 2.851,中科院分区3区,单篇引用次数>100次) [9] Jun Wang#, Qing Wang, Tao Han, Yongkui Li, Shengli Zhu, Fang Ao, Jian Feng, Mingzhen Jing, Li Wang, Linbai Ye, Ying Zhu*. Soluble interleukin-6 receptor is elevated during influenza A virus infection and mediates the IL-6 and IL-32 inflammatory cytokine burst. Cell Mol Immunol,2015 Sep;12(5):633-44. (IF = 7.551) [10] Zheng Wang#, Yeshun Zhang#, Jinxiang Zhang, Lei Huang, Jia Liu, Yongkui Li, Guozheng Zhang, Subhas C. Kundu, Lin Wang*. Exploring natural silk protein sericin for regenerative medicine: an injectable, photoluminescent, cell-adhesive 3D hydrogel. Scientific Reports. 2014; 4:7064-74. (IF = 4.122) [11]Wang, Jian; Yang, Wen; Xie, Hongjian; Song, Yu; Li, Yongkui; Wang, Lin. Ischemic stroke and repair: current trends in research and tissue engineering treatments. Regenerative Medicine Research. 2014, Dec;2(1):No.3. [12] Jiali Fang#, Qian Hao, Li Liu, Yongkui Li, Jianguo Wu, Xixiang Huo, and Ying Zhu*. Epigenetic changes mediated by microRNA miR29 activate cyclooxygenase-2 and lambda-1 interferon production during viral infection. J Virol. 2012; 86:1010-20. (IF = 4.368) [13] Li Liu#, Rui Li, Ying Pan, Jing Chen, Yongkui Li, Jianguo Wu, Ying Zhu*. High-throughput screen of protein expression levels induced by cyclooxygenase-2 during influenza a virus infection. Clin Chim Acta. 2011; 412:1081-5. (IF = 2.926) [14] Wei Li#, Wei Sun#, Li Liu, Fang Yang, Yongkui Li, Yanni Chen, Jiali Fang, Wenjing Zhang, Jianguo Wu and Ying Zhu*. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. J Immunol. 2010; 185:5056-65. (IF =4.539) [15] Xianmiao Wang#, Ying Li, Aiping Mao, Chao Li, Yongkui Li and Po Tien*. Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol. 2010;7:341-8. (IF = 7.551) [16] 徐秀鹏,李永奎,朱应.乙型肝炎重症化进程中病毒学特点及其致病机制.传染病信息2011年8月30日,第24卷,第4期,页码:248-251. 主要著作承担课题1.广东省自然科学基金-面上项目,2020A1515010369,乙肝病毒相关肝细胞癌组织微环境中NLRP3炎症小体促进HCC干细胞活性机制研究,2019.10.01- 2022.09.30, 10万元,主持。 发明专利丝胶蛋白水凝的制备方法及其应用,国家专利授权(专利号 ZL201410071402.0); 一种含有胶原蛋白结合结构域的融合蛋白,国家专利授权(专利号 ZL201610962104.0) 讲授课程《病原微生物学》,专业选修课,2学分,36学时。 荣誉奖励社会职务中国医疗保健国家交流促进会并临床工程与健康产业分会,委员; 湖北医学生物免疫学会并再生医学与免疫专委会,常务委员。 |